Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics

@article{Oo2018DiseasemodifyingDI,
  title={Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics},
  author={W. Oo and S. Yu and M. Daniel and D. Hunter},
  journal={Expert Opinion on Emerging Drugs},
  year={2018},
  volume={23},
  pages={331 - 347}
}
ABSTRACT Introduction: Osteoarthritis (OA) is a leading cause of pain and disability among adults with a current prevalence of around 15% and a predicted prevalence of 35% in 2030 for symptomatic OA. It is increasingly recognized as a heterogeneous multi-faceted joint disease with multi-tissue involvement of varying severity. Current therapeutic regimens for OA are only partially effective and often have significant associated toxicities. There are no disease-modifying drugs approved by the… Expand
New Trends in Pharmacological Treatments for Osteoarthritis
Pharmacotherapy for knee osteoarthritis: current and emerging therapies
The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date
Pharmacodynamics, efficacy, safety and administration of intra-articular therapies for knee osteoarthritis
The emerging role of fibroblast‐like synoviocytes‐mediated synovitis in osteoarthritis: An update
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 199 REFERENCES
Emerging drugs for the treatment of knee osteoarthritis
Emerging drugs for osteoarthritis
The Future of Osteoarthritis Therapeutics: Targeted Pharmacological Therapy
Osteoarthritis: an update with relevance for clinical practice
Monoclonal antibodies for the treatment of osteoarthritis
How to define responders in osteoarthritis
...
1
2
3
4
5
...